ARCHIVES

FDA will return memento given to McClellan by NCI Director Andrew von Eschenbach.

This article is from The Cancer Letter archive.

Vol. 30 No. 06 | February 6, 2004

Download PDF Visit The Full Archive

Related Articles

NSABP Disputed NCI Cost Estimate For P-4 Trial.

May 25, 2007

Monitoring of Clinical Trials Finds Two Major Problems; Investigators Are Suspended

August 19, 1983

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

Who Makes This Drug? Secretive Contract Manufacturing Agreements Complicate Solutions to Shortages of Generics

January 3, 2014

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

Congressional Panel Is Investigating FDA Oversight Of Generic Cancer Drugs

August 18, 1995